An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.


An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.

Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.

Independence Day. I can’t wait. Generally, it’s not a holiday that carries a lot of meaning for me. Having grown up in New York and Boston, the smaller firework displays that take place in Baltimore fail to impress. Also, as a program director, the holiday falls in the middle of the new fellows’ first week…

Sarah F. Keller, MD, & Marcy B. Bolster, MD |
It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteoporosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

The Lupus and Allied Diseases Association Inc. established the Marc R. Chevrier, MD, PhD, FACR, Lupus Research Memorial Fund at the Rheumatology Research Foundation, effective March 1. This fund was established to honor the life and legacy of Marc Chevrier, MD, PhD, FACR, a pioneer and patient advocate in the field of lupus. About Dr….

As more people get vaccinated for COVID-19, there’s hope that the long days of a pandemic, which has claimed more than 2.5 million lives globally and 500,000 in the U.S., will soon draw to a close and allow daily life to return to normal. However, for some people, this recovery may take longer, because the…

As a member of the ACR Government Affairs Committee, Mohammad Kamran, MD, has embraced virtual advocacy as a way to make a difference for patients during the COVID-19 pandemic and beyond.

Larry Beresford |
Despite revolutionary advances in pharmacologic treatments for many rheumatic conditions in recent years, some patients still fail to reach a desired state of living with their disease, notes R. Swamy Venuturupalli, MD, FACR, a clinician and researcher in rheumatology, as well as the founder and director of Attune Health, a Beverly Hills, Calif.-based company that…

Matthew J. Herrmann, MD, & Faizah Siddique, MD |
Rheumatologists are in the unique position of diagnosing and treating rare auto-inflammatory and autoimmune diseases. Although systemic lupus erythematosus (SLE) often has textbook presentations, it is a heterogeneous condition with a wide variety of disease manifestations. In 2019, the European League Against Rheumatism and the ACR introduced new classification criteria to help diagnose this condition.1…

Pooja Gangwani, DDS, MPH |
Medication-related osteonecrosis of the jaw (MRONJ) is a condition that manifests as exposed, necrotic and non-healing jaw bone in patients who have been treated with bisphosphonates, denosumab, chemotherapeutic agents, anti-angiogenic drugs, tyrosine kinase inhibitors, thalidomide and steroids.1-4 These medications are administered via intravenous, subcutaneous and oral routes to manage osteopenia; osteoporosis; hypercalcemia of malignancy; bone…